Zosano Pharma (ZSAN) Stock Price, News & Analysis

Zosano Pharma Co. (NASDAQ:ZSAN) released its quarterly earnings results on Friday, May, 13th. The biotechnology company reported ($1.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.75) by $0.01. Zosano Pharma had a negative trailing twelve-month return on equity of 177.06% and a negative net margin of 8,375.11%.

Shares of Zosano Pharma reverse split on the morning of Tuesday, April 12th 2022. The 1-35 reverse split was announced on Tuesday, April 12th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 12th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zosano Pharma investors own include Aeterna Zentaris (AEZS), Pennsylvania Real Estate Investment Trust (PEI), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Novan (NOVN), Hallador Energy (HNRG) and EnLink Midstream (ENLC).

Zosano Pharma (ZSAN) raised $47 million in an IPO on Tuesday, January 27th 2015. The company issued 4,300,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.